These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28109908)

  • 1. Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer.
    Noronha V; Patil VM; Joshi A; Chougule A; Banavali S; Prabhash K
    Cancer Lett; 2017 Aug; 400():267-275. PubMed ID: 28109908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer.
    Roberto M; Romiti A; Onesti CE; D'Antonio C; Milano A; Falcone R; Barucca V; Palombi L; Righini R; Marchetti P
    Anticancer Drugs; 2016 Feb; 27(2):106-11. PubMed ID: 26473528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving treatments for advanced gastric cancer: appraisal of the survival trend.
    Roberto M; Romiti A; Onesti CE; Zullo A; Falcone R; Marchetti P
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):717-29. PubMed ID: 27137418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
    Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
    Bichev D; Treese C; von Winterfeld M; Breithaupt K; Dogan Y; Schmidt SC; Daum S; Thuss-Patience PC
    Oncology; 2015; 89(2):95-102. PubMed ID: 25823985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
    Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
    World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
    Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
    Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
    Hofheinz RD; Lorenzen S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):607-14. PubMed ID: 26035718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic weekly paclitaxel in advanced unresectable esophageal cancer.
    Noronha V; Patil V; Bhosale B; Joshi A; Purandare N; Prabhash K
    Indian J Cancer; 2013; 50(2):128-34. PubMed ID: 23979204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer.
    Shi M; Ma T; Xi W; Jiang J; Wu J; Zhou C; Yang C; Zhu Z; Zhang J
    Trials; 2020 Mar; 21(1):249. PubMed ID: 32143730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
    Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.
    Brenner B; Sarfaty M; Purim O; Kundel Y; Amit L; Abramovich A; Sadeh Gonik U; Idelevich E; Gordon N; Medalia G; Sulkes A
    PLoS One; 2016; 11(7):e0157548. PubMed ID: 27390847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
    Montagna E; Palazzo A; Maisonneuve P; Cancello G; Iorfida M; Sciandivasci A; Esposito A; Cardillo A; Mazza M; Munzone E; Lai A; Goldhirsch A; Colleoni M
    Cancer Lett; 2017 Aug; 400():276-281. PubMed ID: 28131905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
    Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
    BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
    Petry V; Gagliato DM; Leal AI; Arai RJ; Longo E; Andrade F; Ricci MD; Piato JR; Barroso-Sousa R; Hoff PM; Mano MS
    Braz J Med Biol Res; 2015 May; 48(5):479-85. PubMed ID: 25760024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
    van Meerten E; Eskens FA; van Gameren EC; Doorn L; van der Gaast A
    Br J Cancer; 2007 May; 96(9):1348-52. PubMed ID: 17437008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
    Berenato R; Morano F; Pietrantonio F; Cotsoglou C; Caporale M; Infante G; Pellegrinelli A; Alessi A; Battiston C; Coppa J; Padovano B; Mennitto A; Niger M; Fucà G; Lazzati S; Greco G; Delconte G; de Braud F; Mazzaferro V; Di Bartolomeo M
    Oncology; 2017; 93(5):279-286. PubMed ID: 28881354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.